Day: May 8, 2023

VANCOUVER, British Columbia, May 08, 2023 (GLOBE NEWSWIRE) — MindBio Therapeutics (CSE:MBIO) is one of the latest new listings on the Canadian Securities Exchange. Based in Melbourne, Australia, MindBio Therapeutics is pioneering clinical studies into the micro-dosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. A Media Snippet accompanying this announcement is available by clicking on the image or link below:For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on “InvestmentPitch” and on “YouTube”. If these links are not enabled, please visit www.InvestmentPitch.com and enter “MindBio Therapeutics” in the...

From Japan to Mexico to the World: “The Metabolism for Life” AUSTIN, May 08, 2023 (GLOBE NEWSWIRE) — Indoor Harvest Corp. (OTCPK: INQD) (the “Company”) a company of sustainable-hemp and wellness related products, is pleased to announce the acquisition of a 60% controlling interest in Metabiogenix USA® for $2.5M in a combination of cash and common stock.   During the close of the acquisition, Metabiogenix USA® received a valuation of $8.9M USD from the Japanese Medical Institute (JMI). “This acquisition will provide Indoor Harvest an exclusive agreement to market and distribute the portfolio of Metabiogenix USA® Nutraceuticals throughout the entire Western Hemisphere (North, South, and Central America), and Spain.  Metabiogenix USA® is on track for substantial growth and projecting revenues that could be as high as $20M for...

Dentsu, FuboTV, GroupM, Havas, LG, Mars, and Omnicom Media Group Germany are the First to Use Activate NO-HEADQUARTERS/REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) — PubMatic (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced the launch of Activate. This groundbreaking new end-to-end supply path optimization (SPO) solution allows buyers to execute non-bidded direct deals on PubMatic’s programmatic platform, accessing premium video and CTV inventory at scale. Initial launch partners include dentsu, FuboTV, GroupM, Havas, LG, Mars, and Omnicom Media Group Germany, among others. Activate represents a new industry paradigm as it is a single layer of technology that directly connects buyers and sellers of digital media. Activate gives buyers more control...

HONG KONG, May 08, 2023 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce solutions for large parcel merchandise, today announced that it was named one of the winners of a Bronze Stevie® Award in the Fastest Growing Company of the Year – Up to 2,500 Employees category in The 21st Annual American Business Awards®. The American Business Awards are the U.S.A.’s premier business awards program. Winners were selected by more than 240 professionals worldwide in the three-month judging process based on their average scores. Other recipients of the American Business Awards include Samsung Electronics America, Verizon, and Cisco Systems, Inc. Larry Wu, Founder, Chairman of the Board of Director and Chief Executive Officer of the Company, commented,...

Highlights:U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND application US Naval Medical Research Centre (NMRC) satisfactorily addressed all clinical hold issues identified by the FDA IND to evaluate the efficacy of new Campylobacter ETEC Therapeutic in two human Phase 2 clinical trials is now active One trial will focus on the ability of the hyperimmune product to prevent infectious diarrhoea caused by ETEC The second trial will focus on protecting volunteers against moderate to severe campylobacteriosisMELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated...

Figure 1 Longitudinal section (looking North) extending from Stock West to East of the historical Stock Mine headframe; three key areas are highlighted with recent drill results.Figure 2 Area A – Longitudinal section (looking North) profiling the upper East portion of the historical Stock Mine.Figure 3 Area B – Longitudinal section (looking North) showing the potential mineralized areas at Stock Main.Figure 4 Area C – Longitudinal section (looking North) showing the outline (in red) of the PEA resource for Stock West. Also shown is the postulated shallow plunge (to the South-West) for the Stock West deposit.High Grades Near Surface in Proximity to the Proposed Ramp System to Stock West Hole SM23-145: 18.9 g/t Au over 9.4 m Hole SM22-116: 18.7 g/t Au over 3.0 m Hole SM23-133: 11.9 g/t Au over 2.6 m TORONTO,...

RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, May 11, 2023. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.Conference Call & Webcast Detail: Date: Thursday, May 11, 2023Time:  8:30 a.m. Eastern TimeLink: https://register.vevent.com/register/BIda2814a842e34d0d825731a73c51d74d To access the conference call, please register using https://register.vevent.com/register/BIda2814a842e34d0d825731a73c51d74d. Upon registration, a dial-in number and unique PIN will be provided to join the call....

EVLI PLC STOCK EXCHANGE RELEASE ON MAY 8, 2023, AT 1:10 PM (EET/EEST) The Board of Directors of Evli Plc has in its meeting on April 25, 2023 approved request of shareholders to convert 18,000 Series A shares of Evli Plc to Series B shares in accordance with Article 4 in the Articles of Association. As a result of the conversion of shares, the company’s amount of Series A shares totals 14,467,148 and the amount of Series B shares totals 11,808,154. The conversion does not affect the total amount of shares which is 26,275,302. The number of votes of the company’s shares is after the conversion 301,151,114. The conversions of shares were registered in the Trade Register on May 8, 2023. The converted shares will be listed on the Nasdaq Helsinki together with the old shares on May 9, 2023. EVLI PLC Additional information:Juho Mikola,...

MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) — Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company’s Chief Financial Officer will present at the JMP Securities Life Sciences Conference being held in New York City on May 15-16 2023. Mr.Morris will present on Tuesday, May 16th at 1:00 pm ET (3:00 am May 17th AEDT), which can be accessed live by registering at https://wsw.com/webcast/jmp59/opt/1565103.  An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/. About Opthea Limited Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address...

Copenhagen, May 08, 2023 (GLOBE NEWSWIRE) — Announcement no. 3–2023Annual ReportThe board of directors for the media tech company Hypefactors has approved the revised annual report for 2022. Revenue for the period amounted to DKK 9.384m, compared to DKK 6.787m in 2021, corresponding to an increase of 38%. Earnings before interest, tax, depreciation, and amortization (EBTIDA) amounted to a positive of 0.333m, compared to 2021 which showed a negative EBTIDA of DKK 2.073m. Hypefactors reached an annual recurring revenue (ARR) of DKK 10.625 per December 31, 2022, (2021: 7,751m) which is an increase over the last twelve months of 37%.—- About Hypefactors A/S Hypefactors is an integrated AI powered Earned Media tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to...